Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • EAMS

    - PMLiVE

    Roche’s Columvi improves survival in large B-cell lymphoma

    Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

    - PMLiVE

    Roche receives FDA clearance for whooping cough test

    There are around 24.1 million cases of whooping cough annually, with around 170,000 deaths

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Genentech announces positive clinical results for BTK inhibitor MS treatment

    Multiple sclerosis affects more than 2.9 million people globally

    - PMLiVE

    MHRA marks 100 years of patient safety through biological standards

    The UK regulator highlights its century-long role in establishing safety and consistency benchmarks

    - PMLiVE

    MHRA and FDA expand collaboration on AI and medtech regulation

    National Commission on the Regulation of AI in Healthcare brings together UK and US experts

    - PMLiVE

    Roche’s small cell lung cancer therapy approved by FDA

    This is the first and only approved combination therapy for extensive-stage small cell lung cancer

    - PMLiVE

    Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

    The recommendation for the subcutaneous formulation follows encouraging trial data

    - PMLiVE

    Ipsen’s tumour treatment receives MHRA marketing authorisation

    This is the first approval in the UK for previously treated advanced neuroendocrine tumours

    - PMLiVE

    New National Commission launched to strengthen AI regulation

    The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance

    - PMLiVE

    Roche to acquire 89bio in a deal worth up to US$3.5bn

    With the agreement, Roche will gain a treatment for moderate to severe MASH

    - PMLiVE

    Genentech starts construction on manufacturing facility in North Carolina, US

    The $700m project is part of Roche’s $50bn investment in the US

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links